Kamiren (Doxazosin)

Doxazosin is an alpha‑1 adrenergic blocker that selectively antagonizes peripheral alpha‑1 receptors, leading to vasodilation and relaxation of smooth muscle in the prostate. By lowering systemic vascular resistance and easing urinary outflow obstruction, it is employed in clinical practice for conditions that involve elevated blood pressure and prostate enlargement.

• Hypertension: reduces systolic and diastolic blood pressure by decreasing peripheral vascular resistance.
• Benign prostatic hyperplasia: improves urinary flow and decreases nocturia by relaxing prostatic smooth muscle.

• Doxazosin selectively binds to alpha‑1 adrenergic receptors located on vascular smooth muscle and prostatic stromal cells. By blocking the receptor’s response to norepinephrine, it prevents calcium‑mediated contraction, causing vasodilation of peripheral arteries and relaxation of prostatic smooth muscle. The resulting decrease in systemic vascular resistance lowers arterial pressure, while the prostate relaxation improves urinary outflow. The effect is dose‑dependent and reversible upon discontinuation.

Doxazosin may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially on standing.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Nasal congestion: blockage or runny nose.
• Peripheral edema: swelling of ankles or feet.
• Reflex tachycardia: compensatory increase in heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Syncope: sudden loss of consciousness.
• Angioedema: swelling of face, lips, or throat.
• Priapism: prolonged painful erection.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Doxazosin, clinicians should consider several safety measures.

• Blood pressure monitoring: check baseline and periodically after initiation.
• Dose titration: start low and increase gradually to minimize orthostatic hypotension.
• Concomitant antihypertensives: may enhance hypotensive effect, requiring dose adjustment.
• Renal or hepatic impairment: consider dose reduction and close monitoring.
• Pregnancy and lactation: use only if potential benefits justify potential risks.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Doxazosin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Other alpha‑blockers: additive hypotension.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of profound hypotension.
• Potassium‑sparing diuretics: may increase hyperkalemia risk.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask tachycardia response.
• Loop or thiazide diuretics: may exacerbate orthostatic hypotension.
• CYP3A4 inhibitors (e.g., erythromycin): may raise plasma levels of Doxazosin.